Physician profile
Nehal Patel
NPI 1750686283
$1,854.14
in general payments reported to CMS, 2019-2025
28 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.38 · 2021: $197 · 2022: $403 · 2023: $386 · 2024: $419 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.46 | 2021-2025 | |
| Lilly USA, LLC | $249.24 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $150.00 | 2021-2024 | |
| Amgen INC. | $135.69 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $106.18 | 2022-2024 | Verquvo |
| Abbott Laboratories | $103.97 | 2023-2024 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $92.56 | 2019-2025 | Farxiga, Brilinta, Breztri |
| Astellas Pharma US INC | $80.32 | 2024-2025 | Veozah |
| Pfizer INC. | $73.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.67 | 2023-2025 | Jardiance, Synjardy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.55 | 2021-2023 | Lifevest |
| Exact Sciences Corporation | $59.99 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $52.35 | 2021-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $35.74 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $29.85 | 2023-2024 | Trelegy Ellipta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $29.28 | 2025 | Vivitrol |
| Boston Scientific Corporation | $24.62 | 2025 | Watchman Access System |
| Aimmune Therapeutics, INC. | $24.34 | 2025 | Zenpep |
| Horizon Therapeutics Plc | $22.65 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $21.53 | 2023 | Keveyis |
| Lundbeck LLC | $20.58 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $20.57 | 2025 | |
| Seqirus USA INC | $18.46 | 2025 | Fluad, Flucelvax |
| Dexcom, INC. | $18.17 | 2023 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $17.69 | 2023 | |
| Averitas Pharma INC. | $15.11 | 2025 | Qutenza |
| Amarin Pharma, INC. | $12.19 | 2021 | |
| Biodelivery Sciences International, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.